Answers are grounded in this paper and cite their sources.
This research develops a GMP-compliant process for TBSV-based nanoparticles in autoimmune diseases, highlighting sustainability and market potential.
Plant-made nanomaterials are proteinaceous elements that are emerging as multi-purpose and versatile tools in the therapeutic landscape. In the context of autoimmune diseases, Tomato Bushy Stunt Virus (TBSV) has been previously explored as a platform for inducing immune tolerance by displaying disease specific immunodominant peptides, offering a potential path toward disease remission. In this study, we developed a dedicated facility and a GMP-compliant manufacturing process for producing TBSV based nanoparticles engineered to display peptides relevant to specific autoimmune disorders. Data collected from multiple non consecutive pilot scale production batches were used to build a simplified techno-economic model of the process. The process is readily scalable and offers opportunities for further improvements, supporting the potential to meet market demands for early-stage therapeutic interventions in autoimmune diseases. Additionally, an environmental, health, and safety (EHS) assessment of the process demonstrated a highly favorable environmental output index and minimal associated risks, reinforcing the platform sustainability. These results support the viability of plant-based manufacturing for therapeutic nanomaterials and highlight TBSV potential as a novel platform for tolerance-inducing treatments in autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Pivotto et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: